Drug Trial Radar · NCT06677138
PK Study of Gefurulimab SC in Healthy Chinese Adult Participants
Last checked: Nov 19, 2026Latest source record: May 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Oct 28, 2024
Primary completion
Mar 19, 2025
Study completion Mar 19, 2025
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to characterize the PK properties of a single dose of gefurulimab in healthy Chinese participants.
Conditions
- Healthy
Interventions
gefurulimabDrug
Participants will receive gefurulimab subcutaneously (SC).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Serum Concentration (Cmax) of GefurulimabTime frame: Day 1 predose through Day 92 postdose
- Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of GefurulimabTime frame: Day 1 predose through Day 92 postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.